View in EDS HTML Full Text PDF Full Text

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.

Saved in:
Bibliographic Details
Title: Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Authors: Hamlin PA; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Flinn IW; Center for Blood Cancer, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Wagner-Johnston N; Division of Oncology, Washington University, St. Louis, Missouri., Burger JA; Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas., Coffey GP; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California., Conley PB; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California., Michelson G; Clinical Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Leeds JM; Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California., Der K; Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California., Kim Y; Regulatory Affairs, Portola Pharmaceuticals, Inc., South San Francisco, California., Sabalvaro-Torres A; Clinical Operations, Portola Pharmaceuticals, Inc., South San Francisco, California., Birrell M; Corporate Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Pandey A; Medicinal Chemistry and Chemical Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Curnutte JT; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Patel MR; Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida.
Source: American journal of hematology [Am J Hematol] 2019 Apr; Vol. 94 (4), pp. E90-E93. Date of Electronic Publication: 2019 Jan 08.
Publication Type: Clinical Trial, Phase I; Letter; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 30592080
AccessLevel: 2
PubType: Report
PubTypeId: report
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hamlin+PA%22">Hamlin PA</searchLink>; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York.<br /><searchLink fieldCode="AU" term="%22Flinn+IW%22">Flinn IW</searchLink>; Center for Blood Cancer, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Wagner-Johnston+N%22">Wagner-Johnston N</searchLink>; Division of Oncology, Washington University, St. Louis, Missouri.<br /><searchLink fieldCode="AU" term="%22Burger+JA%22">Burger JA</searchLink>; Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Coffey+GP%22">Coffey GP</searchLink>; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Conley+PB%22">Conley PB</searchLink>; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Michelson+G%22">Michelson G</searchLink>; Clinical Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Leeds+JM%22">Leeds JM</searchLink>; Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Der+K%22">Der K</searchLink>; Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Kim+Y%22">Kim Y</searchLink>; Regulatory Affairs, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Sabalvaro-Torres+A%22">Sabalvaro-Torres A</searchLink>; Clinical Operations, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Birrell+M%22">Birrell M</searchLink>; Corporate Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Pandey+A%22">Pandey A</searchLink>; Medicinal Chemistry and Chemical Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Curnutte+JT%22">Curnutte JT</searchLink>; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Patel+MR%22">Patel MR</searchLink>; Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227610369%22">American journal of hematology</searchLink> [Am J Hematol] 2019 Apr; Vol. 94 (4), pp. E90-E93. <i>Date of Electronic Publication: </i>2019 Jan 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Letter; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7610369 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1096-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203618609%22">03618609 </searchLink><i>NLM ISO Abbreviation: </i>Am J Hematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30592080
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ajh.25387
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: E90
    Titles:
      – TitleFull: Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hamlin PA
      – PersonEntity:
          Name:
            NameFull: Flinn IW
      – PersonEntity:
          Name:
            NameFull: Wagner-Johnston N
      – PersonEntity:
          Name:
            NameFull: Burger JA
      – PersonEntity:
          Name:
            NameFull: Coffey GP
      – PersonEntity:
          Name:
            NameFull: Conley PB
      – PersonEntity:
          Name:
            NameFull: Michelson G
      – PersonEntity:
          Name:
            NameFull: Leeds JM
      – PersonEntity:
          Name:
            NameFull: Der K
      – PersonEntity:
          Name:
            NameFull: Kim Y
      – PersonEntity:
          Name:
            NameFull: Sabalvaro-Torres A
      – PersonEntity:
          Name:
            NameFull: Birrell M
      – PersonEntity:
          Name:
            NameFull: Pandey A
      – PersonEntity:
          Name:
            NameFull: Curnutte JT
      – PersonEntity:
          Name:
            NameFull: Patel MR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2019 Apr
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 1096-8652
          Numbering:
            – Type: volume
              Value: 94
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: American journal of hematology
              Type: main
ResultId 1